Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Trabectedin

FDA-approved product (powder, intravenous), marketed as Evdi, Yondelis.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Trabectedin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Dedifferentiated liposarcoma
  • Leiomyosarcoma
  • Liposarcoma
  • Neoplasm
  • Ovarian cancer
  • Ovarian carcinoma
  • Ovarian neoplasm
  • Sarcoma
  • Soft tissue sarcoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other plant alkaloids and natural products
FDA pharmacologic class
Alkylating Drug FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli50.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae47.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis76.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Trabectedin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Trabectedin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • ATREUS - Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM)

    NCT02194231 · start 2013-07

    Registered record
    Registry ID
    NCT02194231
    Conditions
    Malignant Pleural Mesothelioma
    Interventions
    Trabectedin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-07
    Completion
    2019-12-12
    Enrolment
    145

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalignant Pleural Mesothelioma
    InterventionTrabectedin
    PhasePhase 2
    Registry statusCompleted

  • An Observational Study of YONDELIS®+PLD for the Treatment of Patients With Platinum-sensitive Relapse of Ovarian Cancer

    NCT01869400 · start 2013-04

    Registered record
    Registry ID
    NCT01869400
    Conditions
    Recurrent Ovarian Cancer
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2013-04
    Completion
    2017-02
    Enrolment
    83

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Ovarian Cancer
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma

    NCT01692678 · start 2012-08-07

    Registered record
    Registry ID
    NCT01692678
    Conditions
    Advanced or Metastatic Liposarcoma or Leiomyosarcoma
    Interventions
    Trabectedin; Dacarbazine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-08-07
    Completion
    2016-10-11
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced or Metastatic Liposarcoma or Leiomyosarcoma
    InterventionTrabectedin; Dacarbazine
    PhasePhase 3
    Registry statusCompleted

  • Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma

    NCT01189253 · start 2011-05

    Registered record
    Registry ID
    NCT01189253
    Conditions
    Sarcoma
    Interventions
    doxorubicin hydrochloride; trabectedin; laboratory biomarker analysis; quality-of-life assessment
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Terminated
    Start
    2011-05
    Completion
    2015-06
    Enrolment
    133

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcoma
    Interventiondoxorubicin hydrochloride; trabectedin; laboratory biomarker analysis; quality-of-life assessment
    PhasePhase 2 / Phase 3
    Registry statusTerminated

  • Continuing vs Intermittent Trabectedin in Patients With Advanced Soft Tissue Sarcoma

    NCT01303094 · start 2011-02

    Registered record
    Registry ID
    NCT01303094
    Conditions
    Soft Tissue Sarcoma; Uterine Sarcoma
    Interventions
    Trabectedin; Drug: holiday
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-02
    Completion
    2018-08-09
    Enrolment
    53

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSoft Tissue Sarcoma; Uterine Sarcoma
    InterventionTrabectedin; Drug: holiday
    PhasePhase 2
    Registry statusCompleted

  • Trabectedin in Treating Patients With Metastatic Pancreatic Cancer After First-Line Chemotherapy

    NCT01339754 · start 2011-02

    Registered record
    Registry ID
    NCT01339754
    Conditions
    Pancreatic Cancer
    Interventions
    trabectedin; trabectedin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-02
    Completion
    2013-03
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Cancer
    Interventiontrabectedin; trabectedin
    PhasePhase 2
    Registry statusCompleted

  • An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS)

    NCT00796120 · start 2008-11

    Registered record
    Registry ID
    NCT00796120
    Conditions
    Sarcoma
    Interventions
    Trabectedin; Doxorubicin; Ifosfamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-11
    Completion
    2014-08
    Enrolment
    121

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcoma
    InterventionTrabectedin; Doxorubicin; Ifosfamide
    PhasePhase 3
    Registry statusCompleted

  • A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram

    NCT00786838 · start 2008-10

    Registered record
    Registry ID
    NCT00786838
    Conditions
    Solid Tumor
    Interventions
    Trabectedin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-10
    Completion
    2009-12
    Enrolment
    76

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumor
    InterventionTrabectedin; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer

    NCT00569673 · start 2008-03

    Registered record
    Registry ID
    NCT00569673
    Conditions
    Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
    Interventions
    filgrastim; pegfilgrastim; docetaxel; trabectedin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-03
    Completion
    Not recorded
    Enrolment
    71

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
    Interventionfilgrastim; pegfilgrastim; docetaxel; trabectedin
    PhasePhase 2
    Registry statusCompleted

  • An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer

    NCT00580112 · start 2007-06

    Registered record
    Registry ID
    NCT00580112
    Conditions
    Breast Neoplasms
    Interventions
    Dexamethasone; Trabectedin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-06
    Completion
    2011-08
    Enrolment
    127

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Neoplasms
    InterventionDexamethasone; Trabectedin
    PhasePhase 2
    Registry statusCompleted

  • Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma

    NCT00579501 · start 2007-04

    Registered record
    Registry ID
    NCT00579501
    Conditions
    Liposarcoma,Myxoid
    Interventions
    Trabectedin; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-04
    Completion
    2010-01
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiposarcoma,Myxoid
    InterventionTrabectedin; Dexamethasone
    PhasePhase 2
    Registry statusCompleted

  • A Safety Study Utilizing Yondelis and Doxorubicin in Patients With a Type of Cancer Called Soft Tissue Sarcoma

    NCT00102609 · start 2005-04

    Registered record
    Registry ID
    NCT00102609
    Conditions
    Soft Tissue Sarcoma; Sarcoma; Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms
    Interventions
    Doxorubicin; Trabectedin; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-04
    Completion
    2007-10
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSoft Tissue Sarcoma; Sarcoma; Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type +1 more
    InterventionDoxorubicin; Trabectedin; Dexamethasone
    PhasePhase 1
    Registry statusCompleted

  • An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer

    NCT00113607 · start 2005-04

    Registered record
    Registry ID
    NCT00113607
    Conditions
    Ovarian Cancer
    Interventions
    Trabectedin; DOXIL; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-04
    Completion
    2010-11
    Enrolment
    672

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Cancer
    InterventionTrabectedin; DOXIL; Dexamethasone
    PhasePhase 3
    Registry statusCompleted

  • A Phase 2 Study of Trabectedin (Yondelis) in Adult Male Participants With Advanced Prostate Cancer

    NCT00072670 · start 2004-01

    Registered record
    Registry ID
    NCT00072670
    Conditions
    Prostate Cancer
    Interventions
    Trabectedin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-01
    Completion
    2008-11
    Enrolment
    59

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionTrabectedin
    PhasePhase 2
    Registry statusCompleted

  • A Study of ET-743 (Trabectedin) in Patients With Advanced Breast Cancer

    NCT00050427 · start 2002-12

    Registered record
    Registry ID
    NCT00050427
    Conditions
    Breast Neoplasms; Neoplasms; Neoplasms by Site; Breast Diseases; Skin Diseases
    Interventions
    ET743; ET743
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-12
    Completion
    2006-12
    Enrolment
    53

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Neoplasms; Neoplasms; Neoplasms by Site; Breast Diseases +1 more
    InterventionET743; ET743
    PhasePhase 2
    Registry statusCompleted